Medicaments: containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale

In 2024, medicaments: containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale trade exhibited modest growth, with global flows reaching $11,518,466,627 and a three-year compound annual growth rate of +3.9% (five-year: +3.7%). The all-time peak of $11,518,466,627 was recorded in 2024.

Over the 30-year observation window (1995–2024), 79% of years recorded positive growth, indicating a predominantly expanding market. Trend momentum is steady (+0.9% acceleration).

The World Trade Flows Characterization classifies medicaments: containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale as "One-way trade" in the high price range price segment, providing additional context for market positioning and competitive dynamics.

The supply side is diversified (Herfindahl-Hirschman Index 0.088). The three largest exporters — France ($2.0B), Sweden ($1.5B), and United Kingdom ($1.3B) — collectively dominate supply flows. The leading exporter has grown at +7.0% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.058). The three largest import markets are United States ($1.9B), China ($1.1B), and France ($922.5M). The largest importing market sources from 35 different supplying countries.

Estimated substitution elasticity: -17.60. Buyers are highly price-sensitive and can switch between suppliers relatively easily.

The dominant trade corridor is France → United States at $538.3M, representing 28.9% of the importer's total demand.

The volatility score for medicaments: containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale is 4 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, modest but steady demand provides a reasonable entry window. The diversified supply landscape means many competitors but also multiple entry points and buyer relationships to target.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.